Richard Ambinder, MD
Enriched profileJames B. Murphy Professor of Oncology; Director, Division of Hematologic Malignancies and Lymphoma Service, Johns Hopkins Kimmel Cancer Center · Johns Hopkins University School of Medicine
Richard Ambinder is James B. Murphy Professor of Oncology; Director, Division of Hematologic Malignancies and Lymphoma Service, Johns Hopkins Kimmel Cancer Center at Johns Hopkins University School of Medicine. OpenAlex indexes 627 publications with 25,685 citations (h-index 88); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Richard Ambinder, MD, is James B. Murphy Professor of Oncology at Johns Hopkins University School of Medicine / Sidney Kimmel Comprehensive Cancer Center. The public record shows 627 publications with 25,685 citations (h-index 88), centered on Viral-associated cancers and disorders, Lymphoma Diagnosis and Treatment, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 11 registered clinical trials, 19 NIH-funded awards (1985–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Viral-associated cancers and disorders
- 11 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 296.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Sponsor: AIDS Malignancy Consortium
- A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Sponsor: AIDS Malignancy Consortium
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.8%Kinase inhibitor38.5%Brukinsa70%Calquence30%Part D<11 patientsThalidomide Analog17.3%Revlimid100%Part D<11 patientsAnti-infectives
32.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.2%Valacyclovir100%Part D<11 patientsShort-acting sulfonamides13.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsMetabolism & gastrointestinal
11.5%Corticosteroid11.5%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
19 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma
Johns Hopkins University
FY2026$259,527U01CA271252 - Enrichment for Tumor-derived Cell-free EBV DNA: Towards a Diagnostic Assay for Endemic Burkitt Lymphoma
Johns Hopkins University
FY2026$65,268U01CA271252 - Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva
Johns Hopkins University
FY2025$667,061U01CA284811
Congress activity
Updated 27 Aug 2026
46 congress contributions (2006–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Real world safety outcomes of an outpatient lymphoma bispecific antibody program: A single center experience from Johns Hopkins.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients.
JCO oncology practice
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05Hodgkin lymphoma: A review and update on recent progress482 citations2017
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-ambinder-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- M.D.
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - Ph.D. in Pharmacology
Johns Hopkins University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - B.A. in Biochemistry
Harvard College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Program Co-Leader
Hematologic Malignancies and Bone Marrow Transplantation Program, Johns Hopkins Kimmel Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - Site Leader
AIDS Malignancy Consortium (AMC) at Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗ - National Lead
AMC Translational Sciences Working Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hopkinsmedicine.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine